Metformin mitigates aortic valve degeneration in an ex vivo three-dimensional tissue model

Le résumé fourni par la source

Calcific aortic valve disease (CAVD) is a prevalent valvular disorder that lacks effective pharmacological treatments. Metformin, an oral anti-diabetic drug, has been suggested to protect valvular interstitial cells (VICs) from calcification, but its role in preventing organic phosphate-induced degeneration in VICs and aortic valve (AV) leaflets remains unclear. Using an ex vivo three-dimensional tissue model, we induced degeneration with organic phosphate-rich conditions in ovine VICs and AV leaflets. Metformin treatment reduced calcium deposition, as assessed by alizarin red staining (VICs: p < 0.0001; AV leaflets: p < 0.05), and preserved reduced opacity of AV leaflet (p < 0.01). It inhibited early osteogenic differentiation, evidenced by reduced alkaline phosphatase activity (VICs: p < 0.0001; AV leaflets: p < 0.05), and mitigated gene expression of myofibroblastic markers. Furthermore, metformin improved proliferation (VICs: p < 0.0001; AV leaflets: p < 0.05), lowered lactate dehydrogenase levels (VICs: p < 0.01; AV leaflets: p < 0.001), preserved extracellular matrix architecture, and ameliorated extracellular matrix remodeling at gene expression level. AMPK phosphorylation was increased in both VICs (28%, p < 0.001) and AV leaflets (21%, p < 0.05) under pro-degenerative conditions and metformin treatment. In conclusion, metformin protects against organic phosphate-induced degeneration in both VICs and AV leaflets, highlighting its therapeutic potential in CAVD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.